15,818 research outputs found

    Neonatology. Introduction

    Get PDF
    Навчальний посібник містить інформацію про основні принципи догляду за новонародженими дітьми, перехідні умови та годування немовлят, основні принципи реанімації новонароджених. Для англомовних студентів вищих навчальних закладів III-IV рівнів акредитації, аспірантів, неонатологів, сімейних лікарів, педіатрів, терапевтів, акушерів та гінекологів.This study guide contains information about basic principles of care of newborn babies, transitory conditions and feeding of infants, main principles of neonatal resuscitation. For English-speaking students of higher educational institutions of III–IV levels of accreditation, postgraduates, neonatologists, family physicians, pediatricians, internists, obstetricians and gynecologists

    Clinical trials in neonates: ethical issues

    Get PDF
    Clinical trials in neonatology often raise complex ethical problems. This paper suggests that in tackling these it is useful to identify and separate out those elements of the problem that are genuinely ethical (e.g. can I enter a child into a trial if I am not in personal equipoise?) from those that are empirical (e.g. what is the evidence for a treatment's effectiveness?) and those that are formal (e.g. what do codes or the law permit?) The genuinely ethical elements are examples of philosophical problems and must be tackled in a way appropriate to such problems. In practice this usually means some form of systematic argument. This is often frustrating to clinicians who are more used to the assuredness of empirical research. The paper next examines two ethical problems that arise frequently in neonatal trials. The first is equipoise and the related issue of recruiting parents who are not in equipoise because they strongly desire that their baby get the active treatment. We briefly defend the recruitment of such "desperate volunteers". The second is informed consent. We discuss the nature and value of informed consent and suggest that clinicians can often obtain worthwhile consent even in very difficult trials. The final section of the paper uses the example of clinical trials for brain injury to illustrate the difficulties.</p

    Prenatal tobacco smoke exposure increases hospitalizations for bronchiolitis in infants

    Get PDF
    BACKGROUND: Tobacco smoke exposure (TSE) is a worldwide health problem and it is considered a risk factor for pregnant women's and children's health, particularly for respiratory morbidity during the first year of life. Few significant birth cohort studies on the effect of prenatal TSE via passive and active maternal smoking on the development of severe bronchiolitis in early childhood have been carried out worldwide. METHODS: From November 2009 to December 2012, newborns born at ≥ 33 weeks of gestational age (wGA) were recruited in a longitudinal multi-center cohort study in Italy to investigate the effects of prenatal and postnatal TSE, among other risk factors, on bronchiolitis hospitalization and/or death during the first year of life. RESULTS: Two thousand two hundred ten newborns enrolled at birth were followed-up during their first year of life. Of these, 120 (5.4%) were hospitalized for bronchiolitis. No enrolled infants died during the study period. Prenatal passive TSE and maternal active smoking of more than 15 cigarettes/daily are associated to a significant increase of the risk of offspring children hospitalization for bronchiolitis, with an adjHR of 3.5 (CI 1.5-8.1) and of 1.7 (CI 1.1-2.6) respectively. CONCLUSIONS: These results confirm the detrimental effects of passive TSE and active heavy smoke during pregnancy for infants' respiratory health, since the exposure significantly increases the risk of hospitalization for bronchiolitis in the first year of lif

    Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort

    Get PDF
    BACKGROUND: Respiratory Syncytial Virus (RSV) is one of the main causes of respiratory infections during the first year of life. Very premature infants may contract more severe diseases and 'late preterm infants' may also be more susceptible to the infection. The aim of this study is to evaluate the risk factors for hospitalization during the first year of life in children born at different gestational ages in Italy. METHODS: A cohort of 33-34 weeks gestational age (wGA) newborns matched by sex and age with two cohort of newborns born at 35-37 wGA and &gt; 37 wGA were enrolled in this study for a three-year period (2009-2012). Hospitalization for bronchiolitis (ICD-9 code 466.1) during the first year of life was assessed through phone interview at the end of the RSV season (November-March) and at the completion of the first year of life. RESULTS: The study enrolled 2314 newborns, of which 2210 (95.5 %) had a one year follow-up and were included in the analysis; 120 (5.4 %) were hospitalized during the first year of life for bronchiolitis. Children born at 33-34 wGA had a higher hospitalization rate compared to the two other groups. The multivariate analysis carried out on the entire population associated the following factors with higher rates for bronchiolitis hospitalization: male gender; prenatal treatment with corticosteroids; prenatal exposure to maternal smoking; singleton delivery; respiratory diseases in neonatal period; surfactant therapy; lack of breastfeeding; siblings &lt;10 years old; living in crowded conditions and/or in unhealthy households and early exposure to the epidemic RSV season. When analysis was restricted to preterms born at 33-34 wGA the following variables were associated to higher rates of bronchiolitis hospitalization: male gender, prenatal exposure to maternal smoking, neonatal surfactant therapy, having siblings &lt;10 years old, living in crowded conditions and being exposed to epidemic season during the first three months of life. CONCLUSION: Our study identified some prenatal, perinatal and postnatal conditions proving to be relevant and independent risk factors for hospitalization for bronchiolitis during the first year of life. The combination of these factors may lead to consider palivizumab prophylaxis in Italy
    corecore